the Israeli firm Canfite reports that the goals for phase II clinical trials were reached. After 12 weeks of treatment with CF101 83% of the patients reported improvement and 35% of the patients had a remarkable improvement in symptoms. The results were significant compared to placebo group.
Psoriasis affects 2-3% of the population and its market share is estimated to be 3.5B$. The orally administrated drug suppresses the inflammatory mediator TNF-alpha to relief the symptoms of Psoriasis. The drug was found to be safe for use as well.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment